ERBB2 and breast carcinoma: We regrouped publicly available transcriptomic data of 2627 clinical breast cancer samples into luminal (ER+ luminal A and B tumors), basal (comprising basal-like 1, basal-like 2, mesenchymal and mesenchymal stem-like subtypes of triple-negative breast cancer), HER2-overexpressing tumors and normal breast samples according to characteristic gene expression signatures (Materials and Methods) (Figure 1) [2,22,23,24].